Physician profile
Mitchell L Glaser
NPI 1598789521
$752,281.64
in general payments reported to CMS, 2019-2025
34 companies · $256K in 2025
The $256K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46K · 2020: $11K · 2021: $29K · 2022: $73K · 2023: $149K · 2024: $188K · 2025: $256K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $462K · Travel and Lodging: $58K · Consulting Fee: $43K · Food and Beverage: $27K · Honoraria: $2,275 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $462,357.00 |
| Travel and Lodging | $57,799.21 |
| Consulting Fee | $43,077.75 |
| Food and Beverage | $26,747.58 |
| Honoraria | $2,275.00 |
| Education | $115.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $177,042.58 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| E.R. Squibb & Sons, L.L.C. | $153,376.22 | 2024-2025 | Cobenfy |
| Abbvie INC. | $116,168.16 | 2021-2025 | |
| Alkermes, INC. | $71,584.28 | 2019-2025 | Aristada, Aristada Initio, Lybalvi |
| Supernus Pharmaceuticals, INC. | $66,287.28 | 2021-2025 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $61,505.35 | 2020-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $41,904.11 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $41,439.78 | 2019-2025 | Ingrezza |
| Allergan, INC. | $13,221.73 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $1,895.91 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Lundbeck LLC | $1,658.28 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Merck Sharp & Dohme LLC | $1,081.02 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $871.54 | 2019-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $784.20 | 2021-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $442.75 | 2023-2025 | Auvelity, Sunosi |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $438.11 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $403.14 | 2019-2024 | Jornay Pm |
| Corium, LLC | $366.42 | 2023-2025 | Azstarys, Azstarys |
| Harmony Biosciences LLC | $282.03 | 2024-2025 | |
| Shire North American Group INC | $226.01 | 2019 | |
| Jazz Pharmaceuticals INC. | $217.96 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $200.00 | 2025 | Spravato |
| Indivior INC. | $177.98 | 2022-2024 | Perseris |
| Bausch Health US, LLC | $142.41 | 2022-2023 | Aplenzin |
| Neos Therapeutics, Lp | $138.93 | 2019-2021 | |
| Adlon Therapeutics L.P. | $109.28 | 2019-2021 | |
| Almatica Pharma LLC | $76.16 | 2024 | Loreev Xr |
| Collegium Pharmaceutical, INC. | $64.68 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $52.76 | 2023-2025 | Quviviq, Quviviq |
| Noven Therapeutics, LLC | $48.76 | 2023 | Secuado |
| Tris Pharma INC | $37.50 | 2020-2023 | Dyanavel Xr |
| C2n Diagnostics, LLC | $18.28 | 2025 | Precivityad2 |
| Bioxcel Therapeutics, INC. | $18.04 | 2023 | Igalmi |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Glaser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.